ADC Therapeutics reports 89.8% ORR and 77.6% CR in LOTIS-7 trial of ZYNLONTA + glofitamab in r/r DLBCL

ADC Therapeutics SA

Best ORR 89.8% (44/49); CR rate 77.6% (38/49) across dose levels.
At 150 µg/kg dose, ORR 85.7% and CR 75.0%.
In primary refractory patients (n=25): ORR 80%, CR 64%.
Of 8 prior CAR-T patients, 6 achieved CR.
Grade 3+ neutropenia (32.7%); manageable safety profile overall.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.